Ignite Creation Date:
2025-12-24 @ 12:38 PM
Ignite Modification Date:
2026-01-10 @ 1:52 PM
Study NCT ID:
NCT04850261
Status:
WITHDRAWN
Last Update Posted:
2024-10-30
First Post:
2021-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Injection Free IVF
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Switzerland']}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective, randomized, active controlled proof-of concept trial (phase II)'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'The planned study medication was no longer available in Switzerland', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2021-05-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2024-03-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-10-28', 'studyFirstSubmitDate': '2021-03-01', 'studyFirstSubmitQcDate': '2021-04-19', 'lastUpdatePostDateStruct': {'date': '2024-10-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-04-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-03-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Oocyte collection rate', 'timeFrame': 'It will be reported by the IVF-laboratory 2-5 days after the follicle aspiration', 'description': 'Oocyte collection rate'}, {'measure': 'Number of mature Oocytes', 'timeFrame': 'It will be reported by the IVF-laboratory 2-5 days after the follicle aspiration', 'description': 'Number of mature Oocytes'}, {'measure': 'Fertilisation rate per aspirated oocyte', 'timeFrame': 'It will be reported by the IVF-laboratory 2-5 days after follicle aspiration', 'description': 'Fertilisation rate per aspirated oocyte'}, {'measure': 'Estradiol concentration 10 ±1 day after follicle aspiration', 'timeFrame': 'Blood withdrawal (5 min.) 9-11 days after follicle aspiration', 'description': '9-11 days after the follicle aspiration, venous blood will be drawn in order to determine Estradiol concentration in serum'}, {'measure': 'Progesterone concentration 10 ±1 day after follicle aspiration', 'timeFrame': 'Blood withdrawal (5 min.) 9-11 days after follicle aspiration', 'description': '9-11 days after the follicle aspiration, venous blood will be drawn in order to determine Progesterone concentration in serum'}, {'measure': 'Clinical pregnancy rate per initiated cycle', 'timeFrame': 'Pregnancy test 14-21 days after follicle aspiration', 'description': 'Clinical pregnancy rate (positive pregnancy test 14-21 days after the follicle aspiration) per initiated cycle'}, {'measure': 'Duration of luteal phase', 'timeFrame': '14-21 days after follicle aspiration, if pregnancy test ist negative', 'description': 'If the pregnancy test 14-21 days after the follicle aspiration is negative, we will inquire and document the length of the luteal phase'}], 'primaryOutcomes': [{'measure': 'Treatment tolerability', 'timeFrame': 'It will be assessed between Ovulation induction and follicle aspiration. It takes about 3 minutes to complete in the questionnaire', 'description': 'Treatment tolerability will be measured with the Treatment tolerability subscale of the Fertility Quality of Life (FertiQoL) Treatment questionnaire. The subscale assesses the experience of mental and physical symptoms and disruption in daily life due to treatment. It consists of 4 items. Each item has a set of 5 possible responses, from which patients have to chose the one that most closely reflects how they think and feel.'}, {'measure': 'Discomfort of treatment', 'timeFrame': 'It will be assessed between Ovulation induction and follicle aspiration. It takes about 2 minutes to complete in the questionnaire', 'description': 'The level of discomfort of the treatment encountered by the patients will be measured with 3 Visual Analogue Scale (VAS) questions ranging from 1 - 10 to specifically compare the discomfort imposed by the two treatments.'}], 'secondaryOutcomes': [{'measure': 'Embryo transfer rate', 'timeFrame': 'It will be documented after the embryo transfer (2-5 days after follicle aspiration)', 'description': 'Number of embryos transferred in the two groups'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['In vitro fertilization, IVF', 'GnRHa', 'Ovulation induction'], 'conditions': ['Fertility Disorders']}, 'descriptionModule': {'briefSummary': 'Investigation of Natural Cycle In vitro Fertilisation (NC-IVF) treatment with ovulation induction with a nasal GnRH agonist instead of regular NC-IVF treatment with subcutaneous application of hCG with the objective of increasing treatment tolerability and reducing discomfort while being equally successful in terms of embryo transfer rates.', 'detailedDescription': 'In vitro Fertilisation (IVF) treatments can be performed without gonadotropins to reduce side effects. These kinds of IVF treatments are called Natural Cycle IVF (NC-IVF). As NC-IVFs are almost equally effective as classical IVF with gonadotropins but less stressful, they are preferred by many women.\n\nHowever, a relevant burden in NC-IVF still is the ovulation induction by self-injection of human Chorionic Gonadotropin (hCG).\n\nReplacing hCG injection by a nasally applicable Gonadotropin-Releasing Hormone agonist (GnRHa) might reduce this discomfort. GnRHa are already used to induce ovulation in classical IVF treatments.\n\nThe objective of our study ist to answer the question whether NC-IVF treatment with a nasal GnRH agonist can increase treatment tolerability and reduce discomfort while being equally successful in terms of embryo transfer rates than NC-IVF treatment with subcutaneous application of hCG.\n\nThe study will be a randomized controlled proof-of-concept trial. It will be performed in two steps whereas the power analysis only relates to the first step which is prospective-randomized and will be performed as follows:\n\nStep 1:\n\nPrior to the start of the first NC-IVF treatment cycle the patients will be randomized in equal parts by electronic randomisation to receive either the standard therapy with hCG injection (Intervention A) or the study therapy with nasal GnRHa (Intervention B).\n\n• Intervention A: As soon as the expected follicle size is \\>15 mm, ovulation will be induced by injecting 5.000 IU hCG. The follicle aspiration, including flushing of the follicle will be performed 36 hours later. The transfer of the embryo will be performed 2-5 days after the aspiration.\n\nIn order to determine estradiol- and progesterone concentrations blood will be taken 10±1 days after the hCG application. Pregnancy will be confirmed or excluded by hCG testing in serum or urine 14-21 days after the follicle aspiration. In case of positive hCG testing, clinical pregnancy will be confirmed by vaginal ultrasound 4-6 weeks after follicle aspiration.\n\n• Intervention B: The study therapy (Intervention B) will be performed identically as Intervention A with the following exception: Instead of injecting subcutaneous hCG the patients will apply 1 hub of a GnRHa nasal spray (200 microg Nafarelin) to induce ovulation.\n\nStep 2:\n\nIf there is no pregnancy achieved in the first treatment cycle, the patients will switch to the respective other intervention (cross-over design). This procedure allows for an intraindividual comparison of the main outcomes (treatment tolerability and discomfort). Again, the two interventions will be performed as described in step 1.\n\nQuestionnaires:\n\nAt the beginning of the study, all participants will fill in the Fertility Quality of Life (FertiQoL) Core questionnaire.\n\nFor each treatment cycle, they will additionally fill in the FertiQoL Treatment questionnaire and a set of visual analog scale (VAS) questions concerning the level of discomfort encountered in the treatment.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '42 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Indication for IVF\n* Wish to perform NC-IVF\n* Regular menstruation cycles (26-32 days)\n* Orthotopic localization of ovaries\n* Age 18-42\n* Written informed consent\n\nExclusion Criteria:\n\n* Endometrioses III°-IV°\n* ≥ 3 embryo transfers in previous IVF therapies without pregnancy\n* Contraindications or allergies against study medications\n* \\< 18 and \\> 42 years of age\n* Known or suspected non-compliance\n* Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Enrolment of the investigators, their family members, employees and other dependent persons'}, 'identificationModule': {'nctId': 'NCT04850261', 'briefTitle': 'Injection Free IVF', 'organization': {'class': 'OTHER', 'fullName': 'Insel Gruppe AG, University Hospital Bern'}, 'officialTitle': 'Injection Free Natural Cycle In Vitro Fertilisation by Using a Nasal GnRH Agonist to Induce Ovulation. Is it More Comfortable for Patients and Equally Effective as Subcutaneous hCG Injection?', 'orgStudyIdInfo': {'id': 'BASEC Project-ID 2020-03007'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Intervention A: hCG injection', 'description': 'Ovulation induction by subcutaneous injection of 5.000 IU hCG', 'interventionNames': ['Drug: hCG Injection']}, {'type': 'EXPERIMENTAL', 'label': 'Intervention B: nasal application of Nafarelin', 'description': 'Ovulation induction by nasal application of 200 microgram Nafarelin', 'interventionNames': ['Drug: Nafarelin nasal spray']}], 'interventions': [{'name': 'hCG Injection', 'type': 'DRUG', 'description': 'Ovulation will be induced by subcutaneous hCG injection', 'armGroupLabels': ['Intervention A: hCG injection']}, {'name': 'Nafarelin nasal spray', 'type': 'DRUG', 'description': 'Ovulation will be induced by nasal application of Nafarelin', 'armGroupLabels': ['Intervention B: nasal application of Nafarelin']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Michael von Wolff, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Womens Hospital, Bern, Switzerland'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Insel Gruppe AG, University Hospital Bern', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}